Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharma (VRX) Stock: Still Not so Cheap - Barron's
May 9, 2016 7:12 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Monday following a cautious piece in Barron's published over the weekend.
The report notes that, despite shares... More
Valeant (VRX) Derm NRx Up 2.2% Week-over-Week - RBC Capital
May 6, 2016 8:44 AM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 2.2% WoW, ophth NRx were up 2.7% WoW, and Addyi NRx were down 16.2% WoW.
"For the week ending April 29th, new derm scripts (NRx) were up 2.2% vs. down 2.9% the prior week," Miehm commented. "NRx this week... More
